These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21090829)

  • 1. Impact of bisphosphonates on the risk of atrial fibrillation.
    Howard PA; Barnes BJ; Vacek JL; Chen W; Lai SM
    Am J Cardiovasc Drugs; 2010; 10(6):359-67. PubMed ID: 21090829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrial fibrillation and bisphosphonate therapy.
    Pazianas M; Compston J; Huang CL
    J Bone Miner Res; 2010 Jan; 25(1):2-10. PubMed ID: 20091928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates and atrial fibrillation: clinical trial data suggest possible link.
    Prescrire Int; 2011 Apr; 20(115):96-7. PubMed ID: 21648212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of bisphosphonate therapies and risk of developing atrial fibrillation.
    Bunch TJ; Anderson JL; May HT; Muhlestein JB; Horne BD; Crandall BG; Weiss JP; Lappé DL; Osborn JS; Day JD
    Am J Cardiol; 2009 Mar; 103(6):824-8. PubMed ID: 19268739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoporosis treatments and adverse events.
    Solomon DH; Rekedal L; Cadarette SM
    Curr Opin Rheumatol; 2009 Jul; 21(4):363-8. PubMed ID: 19412101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atrial fibrillation in fracture patients treated with oral bisphosphonates.
    Abrahamsen B; Eiken P; Brixen K
    J Intern Med; 2009 May; 265(5):581-92. PubMed ID: 19141097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
    Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of alendronate and risk of incident atrial fibrillation in women.
    Heckbert SR; Li G; Cummings SR; Smith NL; Psaty BM
    Arch Intern Med; 2008 Apr; 168(8):826-31. PubMed ID: 18443257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.
    Huang WF; Tsai YW; Wen YW; Hsiao FY; Kuo KN; Tsai CR
    Menopause; 2010; 17(1):57-63. PubMed ID: 19680161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis.
    Loke YK; Jeevanantham V; Singh S
    Drug Saf; 2009; 32(3):219-28. PubMed ID: 19338379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies.
    Mak A; Cheung MW; Ho RC; Cheak AA; Lau CS
    BMC Musculoskelet Disord; 2009 Sep; 10():113. PubMed ID: 19772579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate adverse effects, lessons from large databases.
    Abrahamsen B
    Curr Opin Rheumatol; 2010 Jul; 22(4):404-9. PubMed ID: 20473174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of bisphosphonates in older adults: how long is long enough?
    Dunn RL; Bird ML; Conway SE; Stratton MA
    Consult Pharm; 2013 Jan; 28(1):39-57. PubMed ID: 23315281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical tolerability profile of alendronate.
    Watts N; Freedholm D; Daifotis A
    Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis.
    Sharma A; Chatterjee S; Arbab-Zadeh A; Goyal S; Lichstein E; Ghosh J; Aikat S
    Chest; 2013 Oct; 144(4):1311-1322. PubMed ID: 23722644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of atrial fibrillation with use of oral and intravenous bisphosphonates.
    Sharma A; Einstein AJ; Vallakati A; Arbab-Zadeh A; Walker MD; Mukherjee D; Homel P; Borer JS; Lichstein E
    Am J Cardiol; 2014 Jun; 113(11):1815-21. PubMed ID: 24837258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.